EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Differential Effects of Antihypertensive Drugs on Central Blood Pressure: A Randomized Comparison Between Nebivolol and Telmisartan

Subin Lim, Hyungdon Kook, Cheol Woong Yu, Ju Hyeon Kim, Jung-Joon Cha, Hyung Joon Joo, Jin Oh Na, Cheol Ung Choi, Sang Yup Lim, Jae Hyoung Park, Soon Jun Hong, Do-Sun Lim

American Journal of Hypertension · 2026-02-01 · 39 (2) · 303-311

DOI: 10.1093/ajh/hpaf098 ↗
AbstractBibliografische Angaben

Abstract

Abstract BACKGROUND Central blood pressure (CBP) is a better predictor of cardiovascular outcomes than peripheral blood pressure. First- and second-generation beta-blockers have shown poor CBP-lowering effects. However, nebivolol, a third-generation beta-blocker with vasodilatory effects, may be beneficial in lowering CBP. This study compared the CBP-lowering efficacies of nebivolol and telmisartan over a 12-week period in patients with hypertension. METHODS This prospective, randomized, multicenter, open-label, controlled trial evaluated 98 participants with hypertension. For 12 weeks, participants received either nebivolol (n = 49) or telmisartan (n = 49) for 12 weeks with a target blood pressure of ≤140/90 mmHg for the entire period. The primary endpoint was a change in central systolic blood pressure (cSBP) after 12 weeks. RESULTS cSBP reduction at week 12 was significantly less in the nebivolol group than in the telmisartan group (−17.2 vs. −29.3mmHg; between-group difference, 12.7 mmHg; 95% confidence interval [CI], 4.1–21.2; P = 0.004). Central pulse pressure decreased in both groups; however, the difference between the groups was not significant (−8.5 vs. −14.1 mmHg, P = 0.207). The nebivolol group demonstrated a slightly increased augmentation index (AIx), whereas the telmisartan group had a significantly decreased AIx (0.7 vs. −7.3 mmHg; 95% CI, 3.1–13.0; P = 0.002). Heart rate at week 12 was significantly lower in the nebivolol group than that in the telmisartan group (64.2 ± 11 vs. 74.6 ± 11 beats per minute, P < 0.001). CONCLUSIONS Nebivolol was less effective than telmisartan at reducing cSBP. Clinical Trial Registration NCT05328310

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →